Clinical Trial

Genetic Variation in TRAF3IP2 (rs13190932)

Recruiting

Record status

This record was last updated July 25, 2025 (before its estimated June 1, 2026 completion). Its status may not reflect the trial's current state.

Summary

Psoriasis is an immune-mediated inflammatory disease that is highly prevalent worldwide, affecting approximately 2-3% of the world population. It is characterized by red, scaly plaques that can appear on various parts of the body, causing significant physical and psychological burden to affected individuals. The Pathogenesis of PsA involves a complex interplay of genetic, immunological, and environmental factors.Genetic studies have identified several susceptibility loci, including HLA-Cw6 and IL23R, which are shared with psoriasis. Additionally, the presence of certain alleles, such as HLA-B27, is associated with a more severe disease course and a higher likelihood of axial involvement.

Trial Details

NCT Number	NCT07086924
Lead Sponsor	South Valley University
Conditions	Psoriasis, Psoriatic Arthritis
Enrollment	50 participants
Start Date	2025-06-01
Primary Completion	2026-06-01 (estimated)
Study Completion	2026-06-10 (estimated)
Updated on ClinicalTrials.gov	2025-07-25